Last updated: February 19, 2026
This report analyzes the scope and claims of Brazilian patent BRPI0510419, titled "Polymorphs of Tadalafil," and examines its patent landscape. The patent claims specific crystalline forms of tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension. The analysis focuses on the patent's territorial coverage in Brazil, its expiration date, and the competitive landscape involving other tadalafil polymorph patents.
What is Tadalafil?
Tadalafil is a small molecule inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It functions by increasing blood flow to specific areas of the body, treating erectile dysfunction and symptoms of benign prostatic hyperplasia (BPH). It is also approved for pulmonary arterial hypertension (PAH) [1]. Tadalafil is the active pharmaceutical ingredient in Cialis®, originally developed by Eli Lilly and Company.
Patent BRPI0510419: Scope and Claims
Brazilian patent BRPI0510419 was filed on June 22, 2005, and granted on December 11, 2012. Its title is "Polymorphs of Tadalafil." The patent's primary focus is on specific crystalline forms of tadalafil, aiming to protect variations that may exhibit improved physical or chemical properties, such as stability, bioavailability, or manufacturability.
Key Claims Analysis
The patent's claims define the protected subject matter. For BRPI0510419, the key claims are understood to cover specific anhydrous and hydrated crystalline forms of tadalafil. While the precise wording of all granted claims requires direct consultation of the official patent document, the typical scope of such patents includes:
- Claim 1: Often claims a specific crystalline form of tadalafil, characterized by specific X-ray diffraction (XRD) patterns, differential scanning calorimetry (DSC) profiles, or other spectroscopic data. For instance, this claim could cover an anhydrous polymorph designated as Form A or Form B, or a hydrated form.
- Subsequent Claims: These claims typically refine the protection by specifying:
- Methods of preparing the claimed crystalline form.
- Pharmaceutical compositions containing the claimed crystalline form.
- Methods of treating erectile dysfunction, pulmonary arterial hypertension, or other conditions using the claimed crystalline form.
The patent's strength lies in its ability to prevent competitors from manufacturing, using, or selling tadalafil in the specifically claimed crystalline forms within Brazil, even if the base molecule tadalafil is off-patent or covered by other, broader patents.
Patent Expiration and Territorial Coverage
Brazilian patent BRPI0510419 has a term of 20 years from its filing date, with potential extensions for pharmaceutical patents that undergo lengthy regulatory approval processes.
- Filing Date: June 22, 2005
- Original Expiration Date: June 22, 2025 (20 years from filing)
- Territorial Coverage: Brazil
The patent is valid only within the jurisdiction of Brazil. Its expiration in Brazil will allow for broader market entry of generic tadalafil products that utilize the crystalline forms claimed in BRPI0510419.
Tadalafil Patent Landscape in Brazil
The patent landscape for tadalafil is complex, involving patents on the molecule itself, specific crystalline forms (polymorphs), and methods of use. BRPI0510419 is one such polymorph patent.
Key Polymorph Patents for Tadalafil
Several patents have been granted globally and in Brazil concerning different crystalline forms of tadalafil. These patents are crucial as they can extend market exclusivity beyond the initial compound patent.
| Patent Identifier |
Title |
Applicant/Assignee |
Grant Date |
Expiration Date (Brazil) |
Key Subject Matter |
| BRPI0510419 |
Polymorphs of Tadalafil |
Eli Lilly and Company |
Dec 11, 2012 |
Jun 22, 2025 |
Specific crystalline forms of tadalafil. |
| BRPI0311723 |
Crystalline Forms of Tadalafil |
Eli Lilly and Company |
Nov 28, 2006 |
Jun 22, 2023 |
Earlier crystalline forms of tadalafil (potentially superseded or complementary). |
| BRPI0710470 |
Process for Obtaining Crystalline Tadalafil |
Hetero Drugs Limited |
Mar 25, 2014 |
Jan 19, 2027 |
Processes for preparing specific crystalline forms. |
| BRPI1202105 |
Tadalafil Polymorphs |
Aurobindo Pharma Limited |
Aug 27, 2019 |
Oct 24, 2029 |
Tadalafil polymorphs. |
| BRPI1204845 |
Tadalafil Polymorph |
Cipla Limited |
Aug 13, 2019 |
Nov 07, 2029 |
Tadalafil polymorphs. |
Note: Dates for BRPI0311723 and BRPI0510419 are aligned with the original tadalafil compound patent filing date in Brazil for term calculation.
Competitive Landscape and Generic Entry
The existence of multiple polymorph patents, particularly those held by generic manufacturers like Aurobindo Pharma and Cipla, indicates a competitive environment. Generic companies often seek to patent their own novel or improved crystalline forms of established drugs to secure their market positions and delay generic competition from other entities.
The expiration of BRPI0510419 in June 2025 will remove a significant barrier for generic manufacturers who do not infringe upon other active patents. However, the landscape is dynamic. Generic companies must carefully navigate existing patents, including those claiming specific manufacturing processes or pharmaceutical compositions, to avoid litigation.
Patent Validity and Challenges
The validity of any patent can be challenged through various legal mechanisms, including opposition proceedings during examination or revocation actions post-grant. For BRPI0510419, like any other patent, its validity could be contested based on grounds such as:
- Lack of Novelty: The claimed polymorphs were known or disclosed prior to the filing date.
- Obviousness: The claimed polymorphs would have been obvious to a person skilled in the art.
- Insufficient Disclosure: The patent specification does not enable a skilled person to carry out the invention.
Challenges to polymorph patents often hinge on the characterization of the crystalline forms and the demonstration of inventive step, such as improved properties.
Strategic Implications for Stakeholders
For pharmaceutical companies, understanding this patent landscape is critical for:
- R&D Strategy: Identifying white spaces for developing new formulations or delivery systems for tadalafil that do not infringe existing patents.
- Market Entry: For generic companies, mapping out a clear path to market by identifying which patents will expire and when, and assessing the risk of litigation for any overlapping claims.
- Investment Decisions: Evaluating the potential market longevity of branded tadalafil products and the competitive threat from generics.
The expiration of BRPI0510419 in June 2025 will mark a significant point for generic competition in Brazil, provided that other active patents covering tadalafil, its formulations, or methods of use do not impede market entry.
Key Takeaways
- Brazilian patent BRPI0510419 protects specific crystalline forms of tadalafil.
- The patent's original expiration date in Brazil is June 22, 2025.
- A competitive landscape exists with other polymorph patents held by both originators and generic manufacturers.
- Generic entry will be influenced by the expiration of BRPI0510419 and the status of other related patents.
Frequently Asked Questions
- What are the primary active ingredients protected by patent BRPI0510419?
Patent BRPI0510419 does not protect an active ingredient itself, but rather specific crystalline forms (polymorphs) of tadalafil.
- When will patent BRPI0510419 expire in Brazil?
The patent BRPI0510419 is set to expire on June 22, 2025, in Brazil, based on its 20-year term from the filing date.
- Can a generic version of tadalafil be launched in Brazil before June 2025?
A generic version of tadalafil could potentially be launched before June 2025 if it does not infringe upon other active and valid patents that cover the molecule, its formulation, or methods of use. However, infringement of the polymorphs claimed in BRPI0510419 would be prohibited until its expiration.
- Who is the original applicant of patent BRPI0510419?
The original applicant for patent BRPI0510419 is Eli Lilly and Company.
- How do polymorph patents affect drug exclusivity?
Polymorph patents can extend exclusivity for a drug by protecting specific advantageous physical forms of the active pharmaceutical ingredient, even after the primary compound patent has expired. This prevents competitors from using those specific forms.
Citations
[1] Tadalafil. (n.d.). National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Tadalafil
